房颤合并ACS或PCI患者抗栓治疗:AUGUSTUS试验按出血与卒中风险分层的分析
AUGUSTUS试验为2×2析因随机对照研究,纳入4614例房颤合并ACS和/或PCI患者,随机接受阿哌沙班或VKA联合阿司匹林或安慰剂。按HAS-BLED和CHA2DS2-VASc评分分层分析显示,阿哌沙班较VKA减少出血且不依赖基线风险,阿司匹林增加出血,支持多数患者采用阿哌沙班加P2Y12抑制剂而不联用阿司匹林。
要点
- 阿哌沙班较VKA降低出血风险,不受HAS-BLED评分影响(交互P=0.23)。
- 阿司匹林增加出血风险,不受HAS-BLED评分影响(交互P=0.88)。
- 多数房颤合并ACS/PCI患者可用阿哌沙班加P2Y12抑制剂、不用阿司匹林。
核心结论
- 研究结果支持多数房颤合并ACS和/或PCI患者使用阿哌沙班加P2Y12抑制剂而不联用阿司匹林,不受基线出血和卒中风险影响。
研究设计与样本
- AUGUSTUS为开放标签、2×2析因、随机对照试验,4614例房颤合并ACS和/或PCI患者随机接受阿哌沙班或VKA及盲法阿司匹林或安慰剂。
- 本分析按基线HAS-BLED(≤2 vs ≥3)和CHA2DS2-VASc(≤2 vs ≥3)评分分层,采用Cox比例风险模型评估治疗效应。
主要发现
- 4386例(95.1%)患者评分可计算,其中66.8% HAS-BLED≥3,81.7% CHA2DS2-VASc≥3。
- 阿哌沙班较VKA出血更低:HAS-BLED≤2者HR 0.57(95%CI 0.41-0.78),HAS-BLED≥3者HR 0.72(95%CI 0.59-0.88),交互P=0.23。
- 阿司匹林增加出血:HAS-BLED≤2者HR 1.86(95%CI 1.36-2.56),HAS-BLED≥3者HR 1.81(95%CI 1.47-2.23),交互P=0.88。
- 阿哌沙班较VKA降低死亡或住院风险:CHA2DS2-VASc≤2者HR 0.92(95%CI 0.67-1.25),CHA2DS2-VASc≥3者HR 0.82(95%CI 0.73-0.94),交互P=0.53。
临床怎么用
- 对房颤合并ACS和/或PCI且接受P2Y12抑制剂的患者,优先选用阿哌沙班而非VKA。
- 多数此类患者不联用阿司匹林,以降低出血风险。
- 基线HAS-BLED或CHA2DS2-VASc评分高低不改变上述治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of apixaban instead of vitamin K antagonists (VKA) as well as dropping aspirin results in less bleeding and comparable ischemic events in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention treated with a P2Y12 inhibitor. OBJECTIVES: The authors assessed the safety and efficacy of antithrombotic regimens according to HAS-BLED and CHA2DS2-VASc scores in AUGUSTUS (The Open-Label, 2 × 2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention). METHODS: In AUGUSTUS, 4,614 patients were randomized in a 2-by-2 factorial design to open-label apixaban or VKA and blinded aspirin or placebo. The primary endpoint was major or clinically relevant nonmajor bleeding over 6 months of follow-up. Cox proportional hazards models were used to assess treatment effects by baseline HAS-BLED (≤2 vs ≥3) and CHA2DS2-VASc (≤2 vs ≥3) scores. RESULTS: Of 4,386 (95.1%) patients with calculable scores, 66.8% had HAS-BLED ≥3 and 81.7% had CHA2DS2-VASc ≥3. Bleeding rates were lower with apixaban than VKA irrespective of baseline risk (HR: 0.57; 95% CI: 0.41-0.78 [HAS-BLED ≤2]; HR: 0.72; 95% CI: 0.59-0.88 [HAS-BLED ≥3]; interaction P = 0.23). Aspirin increased bleeding irrespective of baseline risk (HR: 1.86; 95% CI: 1.36-2.56 [HAS-BLED ≤2]; HR: 1.81; 95% CI: 1.47-2.23 [HAS-BLED ≥3]; interaction P = 0.88). Apixaban resulted in a lower risk of death or hospitalization than VKA without a significant interaction with baseline stroke risk (HR: 0.92; 95% CI: 0.67-1.25 [CHA2DS2-VASc ≤2]; HR: 0.82; 95% CI: 0.73-0.94 [CHA2DS2-VASc ≥3]; interaction P = 0.53). CONCLUSIONS: Our findings support the use of apixaban and a P2Y12 inhibitor without aspirin for most patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention, irrespective of a patient's baseline bleeding and stroke risk (NCT02415400).
引用
- Harskamp, Fanaroff, Lopes, et al. Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. J Am Coll Cardiol. 2022. PMID: 35115097. doi:10.1016/j.jacc.2021.11.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。